Restoring PML Tumor Suppression to Combat Cancer

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2012 Sep 18

PMID 22983003

Citations 3

Authors

Kamil Wolyniec

Ai-Leen Chan

Sue Haupt

Ygal Haupt

Affiliations

Soon will be listed here.

Citing Articles

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Paul P, Raghu D, Chan A, Gulati T, Lambeth L, Takano E Oncogene. 2016; 35(48):6235-6245.

PMID: 27641331 DOI: 10.1038/onc.2016.159.

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Wolyniec K, Carney D, Haupt S, Haupt Y Front Oncol. 2013; 3:124.

PMID: 23730625 PMC: 3656422. DOI: 10.3389/fonc.2013.00124.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi P Cell Cycle. 2013; 12(11):1722-31.

PMID: 23656786 PMC: 3713131. DOI: 10.4161/cc.24805.

References

Junttila M, Evan G . p53--a Jack of all trades but master of none. Nat Rev Cancer. 2009; 9(11):821-9. DOI: 10.1038/nrc2728. View

Bernardi R, Pandolfi P . Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol. 2007; 8(12):1006-16. DOI: 10.1038/nrm2277. View

Petrie K, Zelent A . Marked for death. Nat Cell Biol. 2008; 10(5):507-9. DOI: 10.1038/ncb0508-507. View

Salomoni P, Dvorkina M, Michod D . Role of the promyelocytic leukaemia protein in cell death regulation. Cell Death Dis. 2012; 3:e247. PMC: 3270264. DOI: 10.1038/cddis.2011.122. View

Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y . PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008; 453(7198):1072-8. PMC: 2712082. DOI: 10.1038/nature07016. View

Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli M . Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010; 18(3):258-67. PMC: 2939729. DOI: 10.1016/j.ccr.2010.08.008. View

Scaglioni P, Yung T, Cai L, Erdjument-Bromage H, Kaufman A, Singh B . A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006; 126(2):269-83. DOI: 10.1016/j.cell.2006.05.041. View

Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T . E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ. 2009; 16(8):1156-66. DOI: 10.1038/cdd.2009.31. View

Yamagishi Y, Shoji I, Miyagawa S, Kawakami T, Katoh T, Goto Y . Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. Chem Biol. 2011; 18(12):1562-70. DOI: 10.1016/j.chembiol.2011.09.013. View

10.

Gurrieri C, Capodieci P, Bernardi R, Scaglioni P, Nafa K, Rush L . Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004; 96(4):269-79. DOI: 10.1093/jnci/djh043. View

11.

Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I . E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood. 2012; 120(4):822-32. PMC: 3709628. DOI: 10.1182/blood-2011-10-387647. View